Modified chitosan micron particle / sodium alginate composite hemostatic sponge as well as preparation method and application thereof

By using a method to prepare a hemostatic sponge composed of modified chitosan micron particles and sodium alginate, combined with treatment with calcium chloride and protocatechuic aldehyde, the problem of poor efficacy of existing hemostatic materials in non-compressible bleeding was solved, achieving rapid hemostasis and easy removal.

CN118987325APending Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410929800.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing hemostatic materials are ineffective in treating non-compressible trunk bleeding and internal bleeding, and are difficult to remove quickly and effectively, which may cause secondary harm to patients.

Method used

A hemostatic sponge was prepared by combining modified chitosan micron particles with sodium alginate, followed by high-pressure homogenization and freeze-drying. The sponge was then treated with calcium chloride solution and protocatechuic aldehyde solution, and then controlled to remove the sponge with sodium carbonate solution, achieving rapid hemostasis and easy removal.

Benefits of technology

It achieves rapid hemostasis, has good antibacterial properties, and can be controlled to remove after hemostasis, reducing secondary damage. It is suitable for effective hemostasis of non-compression wounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004939293550000041
    Figure BDA0004939293550000041
  • Figure BDA0004939293550000051
    Figure BDA0004939293550000051
  • Figure BDA0004939293550000061
    Figure BDA0004939293550000061
Patent Text Reader

Abstract

The invention belongs to the field of medical materials, and particularly discloses a modified chitosan micron particle / sodium alginate composite hemostatic sponge and a preparation method thereof. The preparation method comprises the following steps: (1) dissolving chitosan in an acid solution to prepare a 1-5wt% chitosan solution, then adding alkali to separate out chitosan, carrying out suction filtration and resuspension to obtain a chitosan suspension, and carrying out high-pressure homogenization on the chitosan suspension to obtain a chitosan micron particle suspension; (2) blending the chitosan micron particle suspension with a sodium alginate solution and epoxy chloropropane to obtain a blended solution, and freeze-drying the blended solution to obtain a chitosan micron particle / sodium alginate composite sponge; and (3) respectively soaking the chitosan micron particle / sodium alginate composite sponge in a calcium chloride solution and a protocatechuic aldehyde solution, and washing, dehydrating and drying after soaking to obtain the modified chitosan micron particle / sodium alginate composite hemostatic sponge. The preparation method of the composite hemostatic sponge is simple and easy for large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical materials, and specifically discloses a modified chitosan micron particle / sodium alginate composite hemostatic sponge and a preparation method thereof, and also provides the application of the sponge in medical hemostasis. Background Art

[0002] Bleeding and excessive bleeding pose a huge challenge and burden to the healthcare system. Although the mortality rate of compressible hemorrhages in the extremities and junctions can be greatly reduced by the use of tourniquets and topical hemostatic materials, the treatment of non-compressible truncal hemorrhages and internal bleeding remains a major challenge.

[0003] Hemostasis can be achieved through different mechanisms, including physical adhesion to tissue, chemical interaction and binding with coagulation factors, and absorption of plasma. The use of strong bioadhesives to physically seal bleeding wounds without triggering the coagulation cascade is one of the most popular methods of hemostasis. However, most of the strongest bioadhesives are made of synthetic polymers. Synthetic tissue adhesives, such as cyanoacrylates, are prone to cytotoxicity and immune responses. In addition, compression hemostasis is usually ineffective for penetrating wounds and is not suitable for irregular wounds in the axilla and groin. Hemostatic powders tend to enter blood vessels and form thrombi in penetrating wounds, while other hemostatic methods such as grease or gauze are cumbersome to implement and difficult to stop bleeding quickly.

[0004] Compared with these hemostatic technologies, the emerging hemostatic sponges have some inherent advantages, including: the physical properties of the sponge allow it to absorb liquid to promote the aggregation of blood cells and platelets; its significant compressibility can reduce blood loss through physical hemostasis; through rational design and introduction of other functional components. In the past decade, chitosan, as one of the most important and abundant polysaccharides, has been successfully used as a matrix for the preparation of various functional materials and biomaterials, including hydrogels, aerogels, sponges, etc., due to its excellent hemostatic and antibacterial properties, as well as significant biocompatibility and biodegradability. In particular, some commercial products such as XStat devices, HemCon, Celox, etc. have been successfully developed and widely used.

[0005] However, commercial hemostatic materials cannot be removed on demand and can easily cause secondary damage to patients during debridement. We have made a new application of the cross-linking mechanism of sodium alginate and calcium ions, achieving controllable crushing and removal of hemostatic sponges to avoid secondary damage. We have also combined the characteristics of chitosan to develop a removable hemostatic sponge with both hemostatic and antibacterial properties, which provides a new direction for the controlled removal of medical hemostatic materials. Summary of the invention

[0006] In view of the problems and shortcomings of the prior art, the present invention provides a modified chitosan micron particle / sodium alginate composite hemostatic sponge and a preparation method thereof, and also provides an application thereof in medical hemostasis.

[0007] Based on the above purpose, the present invention adopts the following technical solution:

[0008] In a first aspect, the present invention provides a method for preparing a modified chitosan micron particle / sodium alginate composite hemostatic sponge, comprising the following steps:

[0009] (1) dissolving chitosan in an acid solution to prepare a 1-5 wt% chitosan solution, then adding alkali to precipitate the chitosan, filtering and resuspending to obtain a chitosan suspension, and high-pressure homogenizing the chitosan suspension to obtain a chitosan micron particle suspension;

[0010] (2) blending the chitosan micron particle suspension with a sodium alginate solution and epichlorohydrin to obtain a blended liquid, and freeze-drying the blended liquid to obtain a chitosan micron particle / sodium alginate composite sponge;

[0011] (3) Soaking the chitosan micron particle / sodium alginate composite sponge in a calcium chloride solution and a protocatechuic aldehyde solution respectively, and washing, dehydrating and drying after the soaking to obtain a modified chitosan micron particle / sodium alginate composite hemostatic sponge.

[0012] Preferably, in step (1), deionized water is added to resuspend the chitosan, and the chitosan concentration in the obtained chitosan suspension is ≤2 wt%.

[0013] Preferably, the concentration of sodium alginate in the mixed solution obtained in step (2) is 1 to 5 wt %, and the concentration of epichlorohydrin is 0.1 to 1 wt %.

[0014] Preferably, the concentration of the calcium chloride solution in step (3) is 0.1-2 wt %; the concentration of the protocatechuic aldehyde solution is 0.1-2 wt %.

[0015] Preferably, the acid solution in step (1) is hydrochloric acid with a concentration of 0.1 mol / L; the alkaline solution is sodium hydroxide solution with a concentration of 1 mol / L, and the sodium hydroxide solution is added to make the pH value reach above 9.0 to precipitate chitosan.

[0016] Preferably, the pressure of the high-pressure homogenization in step (1) is 20-50 MPa. Furthermore, the specific process of high-pressure homogenization is: using a high-pressure homogenizer to homogenize the chitosan suspension to a milky white uniform suspension.

[0017] Preferably, in step (3), the immersion is carried out in a calcium chloride solution and a protocatechuic aldehyde solution respectively, wherein the immersion time in the calcium chloride solution is 0.5 to 4 hours, and the immersion time in the protocatechuic aldehyde solution is 0.5 to 4 hours.

[0018] Preferably, the specific process of freeze-drying in step (2) is: pouring the blended liquid into a mold, freezing it at -20°C for 12 hours, and then freezing it at -40°C for 12 hours.

[0019] Preferably, the washing in step (3) uses deionized water and the dehydration uses anhydrous ethanol.

[0020] Preferably, the specific process of the drying in step (3) is: drying at room temperature until the anhydrous ethanol is completely volatilized.

[0021] In a second aspect, the present invention provides a modified chitosan micron particle / sodium alginate composite hemostatic sponge prepared by the preparation method described in the first aspect.

[0022] In a third aspect, the present invention provides the use of the modified chitosan micron particle / sodium alginate composite hemostatic sponge described in the second aspect in medical hemostasis.

[0023] Furthermore, the specific method of medical hemostasis is as follows: when stopping bleeding, the prepared modified chitosan micron particle / sodium alginate composite hemostatic sponge is compressed into a sponge sheet, and the sponge sheet is placed on the wound. The sponge sheet immediately expands and seals the bleeding wound after absorbing blood; when removing, sodium carbonate solution is injected and rinsed to flush the sponge until the sponge structure is completely broken and then removed.

[0024] Furthermore, the concentration of the sodium carbonate solution is 0.1-5wt%.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] 1. The present invention utilizes high pressure average to micronize the alkali-precipitated chitosan, which effectively improves the antibacterial and hemostatic abilities of chitosan. At the same time, combined with the adhesion properties of protocatechuic aldehyde, the two synergistically promote rapid hemostasis of wounds.

[0027] 2. The present invention allows calcium ions to enter the blood when the sponge absorbs blood by soaking in calcium chloride solution, and serves as a coagulation factor to accelerate blood coagulation.

[0028] 3. When the composite hemostatic sponge of the present invention is removed after hemostasis, carbonate ions can be used to quickly replace calcium ions in the composite sponge, thereby achieving controllable removal of the composite hemostatic sponge, providing surgeons with a new method for easily removing wound hemostatic sponges.

[0029] 4. The preparation method of the composite hemostatic sponge of the present invention is simple and easy to produce on a large scale. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 a is the Fourier transform infrared spectra (full wave number) of samples 1 to 3 and comparative sample 1, Figure 1 b is the Fourier transform infrared spectra of samples 1 to 3 and comparative sample 1 (1000-2000cm -1 );

[0031] Figure 2 are scanning electron microscope images of samples 1 to 3;

[0032] Figure 3 a is the density test result diagram of samples 1 to 3 and comparison sample 1. Figure 3 b is the porosity test result diagram of samples 1 to 3 and comparison sample 1. Figure 3 c is the 1-minute swelling rate test result of samples 1 to 3 and comparative sample 1. Figure 3 d is the swelling rate test result diagram of samples 1 to 3 and comparative sample 1 at different time points within 24 hours;

[0033] Figure 4 A diagram showing the stress-strain test method.

[0034] Figure 5 a is the compressive strength result diagram of samples 1 to 3 and comparative sample 1 at 80% strain. Figure 5 b is the stress-strain result diagram of sample 1 at 20%, 40%, 60% and 80% strain. Figure 5 c is the stress-strain result diagram of sample 2 at 20%, 40%, 60% and 80% strain, Figure 5 d is the stress-strain result diagram of sample 2 at 20%, 40%, 60% and 80% strain;

[0035] Figure 6 a is the stress-strain result diagram of samples 1 to 3 and comparative sample 1 at 80% strain. Figure 6 b is the stress-strain result diagram of sample 1 subjected to 1, 5 and 10 cycles of compression at 80% strain. Figure 6 c is the stress-strain result diagram of sample 2 subjected to 1, 5 and 10 cycles of compression at 80% strain. Figure 6 d is the stress-strain result diagram of sample 3 subjected to 1, 5, and 10 cycles of compression at 80% strain;

[0036] Figure 7 The blood compatibility test results of samples 1 to 3 and comparative sample 1 are shown in FIG.

[0037] Figure 8 The cell survival rate test results of samples 1 to 3 and the blank group at 1 day, 3 days and 5 days are shown in the figure;

[0038] Fig. 9 Cell fluorescence photos of samples 1 to 3 and the blank group at 1 day, 3 days, and 5 days;

[0039] Fig.10 The scanning electron microscope photos of the blood cell adhesion test results of samples 1 to 3, comparative sample 1 and gauze at X300, X2000 and X5000 respectively;

[0040] Fig.11 The water contact angle photos of samples 1 to 3 and comparative sample 1;

[0041] Fig.12 a is the 24h colony count photo of samples 1-3 and comparison sample 1, Fig.12 b is the result graph of the inhibition rate of samples 1 to 3 and comparison sample 1 against Escherichia coli. Fig.12 c is the result graph of the inhibition rate of samples 1 to 3 and comparative sample 1 against Staphylococcus aureus;

[0042] Fig.13 The in vitro coagulation index results of samples 1 to 3, comparative sample 1, commercial hemostatic gauze and gelatin sponge are shown in FIG.

[0043] Fig.14 a is the coagulation time result diagram of liver puncture experiment of sample 1, comparative sample 1, commercial hemostatic gauze and blank group mice, Fig.14 b is the blood loss results of liver puncture experiment of sample 1, control sample 1, commercial hemostatic gauze and blank group mice. Fig.14 c is the photo of liver puncture hemostasis experiment of mice in sample 1, control sample 1, commercial hemostatic gauze and blank group, Fig.14 d is the animated model of mouse liver. Fig.14 e is the coagulation time result diagram of the femoral artery hemostasis experiment of sample 1, comparative sample 1, commercial hemostatic gauze and blank group rats, Fig.14 f is the blood loss result of the femoral artery hemostasis experiment of sample 1, comparative sample 1, commercial hemostatic gauze and blank group rats, Fig.14 g is a photo of the femoral artery hemostasis experiment of sample 1, comparative sample 1, commercial hemostatic gauze and blank group rats. Fig.14 h is a diagram of the rat femoral artery hemostasis model;

[0044] Fig.15 a Comparative sample 1 before and after sodium carbonate solution washing, the compressive strength ratio result diagram, Fig.15 b The compressive strength ratio of sample 1 before and after washing with sodium carbonate solution, Fig.15 (c, d, e) are photos of injection fragmentation and clearance of sample 1 after hemostasis was completed in the femoral artery of rats. DETAILED DESCRIPTION

[0045] In order to make the purpose, technical solution and advantages of the present invention clearer and more specific, the present invention is further described in detail by examples below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0046] Example 1 Sample preparation

[0047] (1) 1.2 g of chitosan was dissolved in 46.8 g of 0.1 mol / L hydrochloric acid to prepare a chitosan solution with a concentration of 2.5 wt%, and a sodium hydroxide solution with a concentration of 1 mol / L was added to adjust the pH to 10.0 to precipitate chitosan, and then the solution was filtered. After the filtration, deionized water was added to make up to 100 g and the solution was resuspended to obtain a chitosan suspension with a concentration of 1.2 wt%; the chitosan suspension was homogenized by a high-pressure homogenizer at a pressure of 50 MPa to obtain a uniform suspension showing a milky white color, thereby obtaining a chitosan micron particle suspension;

[0048] (2) adding sodium alginate solution and epichlorohydrin to the chitosan micron particle suspension to obtain a blended liquid, wherein the concentration of sodium alginate in the blended liquid is 3 wt % and the concentration of epichlorohydrin is 0.5 wt %, pouring the blended liquid into a metal mold, freezing at -20°C for 12 h, and then freezing at -40°C for 12 h to obtain a chitosan micron particle / sodium alginate composite sponge;

[0049] (3) Soaking the chitosan micron particle / sodium alginate composite sponge in a 1 wt% calcium chloride solution for 1 hour, and then soaking it in a protocatechuic aldehyde solution for 1 hour. After soaking, washing it with deionized water, dehydrating it with anhydrous ethanol, and then taking it out and drying it at room temperature until the anhydrous ethanol is completely volatilized, thereby obtaining a modified chitosan micron particle / sodium alginate composite hemostatic sponge.

[0050] The protocatechuic aldehyde solution was set with different concentration gradients, corresponding to different sample numbers, as shown in Table 1.

[0051] Table 1 Sample numbers corresponding to protocatechuic aldehyde solutions of different concentrations

[0052]

[0053] Example 2 Performance Test

[0054] (I) Structural characterization of hemostatic sponge

[0055] The attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) was performed using a TENSOR II (Bruker, Germany) at 4000 cm -1 -400cm -1 The infrared spectral structure was determined within the range. The infrared spectral characterization of chitosan (CS), sodium alginate (SA), protocatechuic aldehyde (PA), samples 1 to 3 prepared in Example 1, and comparative sample 1 was performed. The results are as follows Figure 1 shown.

[0056] from Figure 1It can be seen that the sample prepared in Example 1 is better than the raw materials CS and SA at 3500cm -1 The hydroxyl absorption peak at the position is weakened, indicating that the samples prepared in Example 1 are successfully cross-linked by hydroxyl groups. Figure 1 b It can be seen that samples 1 to 3 have a higher relative density than control sample 1 at 1520 cm -1 A new benzene ring skeleton vibration absorption peak appeared at , proving that the sample group was successfully introduced into the catechol group.

[0057] (II) Morphological characterization of hemostatic sponge

[0058] The microscopic morphology of samples 1 to 3 prepared in Example 1 and comparative sample 1 was observed by ultra-high resolution scanning electron microscope (ZEISS Sigma 300, Germany). The results of scanning electron microscope are as follows: Figure 2 shown.

[0059] The specific method is as follows: freeze the sample prepared in Example 1 with liquid nitrogen, then cut a flat cross section with a scalpel, gently blow away excess debris on the surface with an ear bulb, then fix it on a conductive adhesive, spray gold for 60 seconds, and observe it under a field emission scanning electron microscope.

[0060] like Figure 2 As shown, the scanning electron microscope photographs show that the samples prepared in Example 1 all have a pore size of about 80 μm, indicating that the pores of the sample sponge are dense and uniform.

[0061] (III) Swelling, density and porosity test

[0062] Density, porosity and swelling tests were performed on samples 1 to 3 prepared in Example 1 and comparative sample 1. The test results are as follows: Figure 3 shown.

[0063] The specific methods for density, porosity and swelling tests are as follows:

[0064] Density: The sample prepared in Example 1 was made into a cylinder, weighed and the mass was recorded, the diameter and height were measured with a vernier caliper, and then the density was calculated. The experimental result was the average value obtained from at least three measurements.

[0065] Porosity: The porosity of the sample prepared in Example 1 was determined by the ethanol replacement method. The initial mass of the dry sample was recorded by weighing, and then it was immersed in anhydrous ethanol and placed in a vacuum drying oven for vacuum degassing for 1 hour to fully expel the air in the pores. The excess ethanol on the surface was gently wiped off with filter paper and weighed again. The porosity (P) of the sponge was calculated according to formula (1). The final experimental result was the average of five measurements.

[0066]

[0067] Where W0 is the initial mass of the sample (g), W e is the mass of the sample absorbed by anhydrous ethanol to reach equilibrium (g), and ρ is the density of ethanol (0.79 g / cm 3 ), V is the sample volume (m 3 ).

[0068] Swelling test: The PBS / blood absorption capacity was tested by weight method. First, the dry weight of the sample prepared in Example 1 was measured, and then it was put into 37°C PBS solution / blood. After the liquid was fully absorbed, it was taken out and the excess liquid on the surface was gently wiped off with filter paper. The absorption rate of PBS solution / blood was calculated according to formula (2):

[0069]

[0070] Wherein, W1 is the mass of the sample in dry state (g), and W2 is the mass of the sample after swelling equilibrium (g).

[0071] from Figure 3 It can be seen from a that the density of comparison sample 1 and samples 1 to 3 are 0.0381 g / cm -3 , 0.0407g / cm -3 , 0.0428g / cm -3 and 0.0458 g / cm -3 This indicates that samples 1 to 3 and comparative sample 1 all have lower density and are light in weight.

[0072] from Figure 3 b It can be seen that the porosity of comparative sample 1 and samples 1 to 3 are 93.0%, 92.9%, 92.5% and 92.2% respectively, which indicates that samples 1 to 3 and comparative sample 1 have higher porosity, ensuring higher liquid absorption performance and stronger liquid absorption capacity.

[0073] from Figure 3 c It can be seen that the one-minute swelling degrees of comparative sample 1 and samples 1 to 3 are 24.6 g / g, 22.9 g / g, 21.8 g / g, and 22.2 g / g, respectively, indicating that samples 1 to 3 and comparative sample 1 have high liquid absorption capacity.

[0074] from Figure 3 d It can be seen that the comparative sample 1 and samples 1 to 3 have the ability to absorb about 20 times the dry weight of the aqueous solution within 5 seconds, indicating that samples 1 to 3 and the comparative sample 1 have the ability to absorb liquid quickly.

[0075] (IV) Mechanical properties test

[0076] Mechanical properties are evaluated by physical property analyzer. Test methods include Figure 4 shown.

[0077] After samples 1 to 3 prepared in Example 1 and comparative sample 1 absorbed deionized water to equilibrium, a compression performance test was performed at a compression rate of 0.5 mm / s under a compression strain of 80%. The compression strengths thereof are shown in FIG. Figure 5 The stress-strain results are shown in a. Figure 6 As shown in a.

[0078] Samples 1 to 3 were compressed at 20%, 40%, 60% and 80% strain respectively, and their stress-strain results are shown in Figure 5 (b,c,d).

[0079] Samples 1 to 3 were subjected to 1, 5, and 10 cycles of compression at 80% strain, respectively. The stress-strain results are shown in Figure 6 (b,c,d).

[0080] from Figure 5 It can be seen from a that the comparative sample 1 and samples 1 to 3 have compressive strengths of 67.2 kPa, 67.0 kPa, 84.9 kPa and 115.0 kPa, respectively, under a compressive strain of 80%. With the increase of the concentration of the protocatechuic aldehyde solution, the compressive strength of the samples increases. Figure 6 a also reflects this trend, which is due to the Schiff base reaction between protocatechuic aldehyde and chitosan to introduce catechol groups into the sponge skeleton. The metal coordination effect of catechol groups and calcium ions enhances the mechanical properties of the sponge skeleton.

[0081] from Figure 5 (b, c, d) It can be seen that the curves at the four strain levels of 20%, 40%, 60%, and 80% are basically able to overlap, showing that the sample has good deformation recovery ability. Figure 6 (b, c, d) It can be seen that although the stress-strain curves after the 1st, 5th and 10th cycle compression do not completely overlap, the compression strength can still retain more than 80%, which means that the sample still exhibits excellent deformation recovery properties after multiple compressions. When squeezed or collided, the hemostatic sponge inside the wound is not easy to fall off, and it still maintains a good filling effect on the wound.

[0082] Based on the above results, it is shown that the compression strength of the modified chitosan micron particle / sodium alginate composite hemostatic sponge is sufficient to withstand the human arterial blood pressure, provide higher physical support and internal compression for non-compressible wounds, and is conducive to rapid hemostasis of non-compressible wounds.

[0083] (V) Blood compatibility test

[0084] The blood compatibility test was performed on samples 1 to 3 prepared in Example 1 and comparative sample 1. The test results are as follows: Figure 7 .

[0085] The specific method of blood compatibility test is:

[0086] The defibrinated sheep blood was centrifuged at room temperature, the supernatant was removed, and then rinsed with PBS solution and centrifuged again. This was repeated three times until the supernatant was clear. The obtained red blood cell precipitate was diluted with PBS solution to 5% (v / v) of the initial concentration. The sample prepared in Example 1 was crushed into powder, and PBS solution was added to prepare five sample dispersions with concentrations of 0.5, 1, 2, 4, and 8 mg / mL, respectively. 0.5 mL of the diluted red blood cell suspension and 0.5 mL of the sample dispersion were added to a 2 mL test tube and mixed evenly. Deionized water and PBS solution were used as positive and negative controls, respectively. All test tubes were incubated at 37°C for 1 h, and then centrifuged at 3000 rpm for 5 min. The supernatant was taken, and the absorbance at 540 nm was measured using an enzyme marker, and the hemolysis rate was calculated according to formula (3):

[0087]

[0088] Among them, OD s is the sample absorbance, OD p is the absorbance of the positive control, OD n is the absorbance of the negative control.

[0089] from Figure 7 It can be seen that the hemolysis rates of samples 1 to 3 and comparative sample 1 are all lower than 5%, showing good blood compatibility.

[0090] (VI) Cytotoxicity test

[0091] Cytotoxicity tests were performed on samples 1 to 3 and comparative sample 1 prepared in Example 1, wherein the cell survival rates at 1 day, 3 days and 5 days were as follows: Figure 8 As shown, the cell fluorescence photos are Fig. 9 shown.

[0092] The specific method of cytotoxicity test is:

[0093] The sample prepared in Example 1 was placed in DMEM / F12 and continuously extracted for 24 hours to obtain a sample extract. L929 mouse fibroblasts were cultured at 1×10 4 The cells were inoculated in a 96-well plate at a density of 10 cells / well. After culturing for 1 day, the cells were cultured with sample extracts, and the extracts were replaced every 2 days. After the culture was completed, 10 μL of CCK-8 was added to each well and incubated in a 37°C incubator for 2 h. The absorbance (OD) was read by a microplate reader at 450 nm, and the cell viability was calculated according to formula (4). Five parallel experiments were performed for each sample, and the average value was reported.

[0094]

[0095] Among them, OD s is the sample absorbance, OD r OD0 is the absorbance value of the positive control, and OD1 is the absorbance value of the negative control.

[0096] Cell live / dead fluorescence staining: L929 mouse fibroblasts were seeded in 24-well plates (5×10 4 Cells were cultured with sample extracts (10 μL calcein-AM (2 μM) and 15 μL PI (4.5 μM) per well after culture and incubated at 37°C in the dark for 10 min. Live and dead cells were detected under a fluorescence microscope at 490 ± 10 nm.

[0097] like Figure 8 It can be seen that the relative cell activities of samples 1 to 3 on day 1 of culture were 84.2%, 81.9% and 84.8%, respectively. After 3 days of continuous culture, the relative cell activities were 98.7%, 95.7% and 100.5%, respectively, which were significantly higher than that on day 1. After 5 days of continuous culture, the relative cell activities were 101.1%, 99.7% and 100.4%, respectively.

[0098] From the relative cell activity and live / dead cell fluorescence staining photos ( Fig. 9 ) analysis, the samples had a certain inhibitory effect on cell activity at the beginning of the experiment, which was caused by the residual trace amount of protocatechuic aldehyde small molecules in the samples. According to the cytotoxicity level of ISO / TC194, samples 1 to 3 all showed good cell compatibility. Combined with the live and dead cell fluorescence staining photos, the growth status of mouse fibroblasts cultured in sponge extract for 1, 3, and 5 days, the mouse fibroblasts cultured in samples 1 to 3 all showed good growth status.

[0099] The above results show that the modified chitosan microparticles / sodium alginate composite hemostatic sponge has good blood compatibility and cell compatibility, and meets the requirements of hemostatic sponge as a hemostatic material.

[0100] (VII) Blood cell adhesion test

[0101] The blood cell adhesion test was performed on samples 1 to 3 prepared in Example 1 and comparative sample 1. The test results were scanned by electron microscope at X300, X2000 and X5000 respectively. The scanning results are shown in FIG. Fig.10 shown.

[0102] The specific method of blood cell adhesion test is:

[0103] Fresh human blood was dripped onto dry gauze, control sample 1, and samples 1 to 3, incubated at 37°C for 1 h, then rinsed with PBS buffer, fixed with glutaraldehyde solution, and dehydrated with ethanol step by step. Finally, the samples were dried in air and observed by SEM.

[0104] from Fig.10 It can be seen that compared with gauze, the comparative sample 1 and samples 1 to 3 all adhere to more blood cells, showing better adhesion performance. In addition, the comparative sample 1 and samples 1 to 3 can all clearly observe activated platelets, proving that the composite sponge has the effect of promoting blood coagulation.

[0105] (VIII) Hydrophilicity test

[0106] The hydrophilicity test was conducted on samples 1 to 3 prepared in Example 1 and comparative sample 1. The water contact angle results are as follows: Fig.11 shown.

[0107] The specific method of hydrophilicity test is:

[0108] The sample prepared in Example 1 was prepared into a thin sheet with a diameter of 10 mm and a thickness of 3 mm, fixed on a glass slide with double-sided tape, and placed on the sample stage of the fully automatic contact angle tester. 3 μL of deionized water was automatically dripped onto the sample surface, and the contact angle was calculated using the tangent method after the droplet was stable for 30 seconds, and a static contact angle photo was captured. The experimental results were the average values ​​of five different positions.

[0109] from Fig.11 It can be seen that at 0.1 s, the water contact angles of samples 1 to 3 and comparative sample 1 are all 0°, which verifies that the samples reflected by the swelling degree line graph have the ability to absorb liquid quickly.

[0110] (IX) Antibacterial ability test

[0111] The antibacterial ability of samples 1 to 3 prepared in Example 1 and comparative sample 1 was tested, wherein the 24-hour colony count results are as follows: Fig.12 As shown in a, the inhibition rate of Escherichia coli is as follows Fig.12 As shown in b, the inhibition rate of Staphylococcus aureus is Fig.12 As shown in c.

[0112] The specific method of antibacterial ability test is:

[0113] Experimental group: The sample prepared in Example 1 was moistened with sterile PBS solution and the excess water was squeezed out. After sterilization, E. coli (10 6 CFUs / mL), Staphylococcus aureus (10 7CFUs / mL) bacterial suspension was dropped on the sample surface (the blank group dropped the same concentration of bacterial suspension on the cell culture plate) and cultured at 37°C for 4 h. 100 μL of bacterial suspension was added to 450 μL of sterile PBS solution for dilution in each of the experimental group and the blank group to obtain the final diluted bacterial suspension (E.coil concentration was 10 3 CFUs / mL, S. aureus concentration is 10 4 CFUs / mL), the bacterial suspension was spread on the agar nutrient medium and cultured at 37°C for 24 h to form microbial colonies and count them. The antibacterial activity was examined by comparing the colony numbers.

[0114] The antibacterial ability of the comparative sample 1 and samples 1 to 3 against E.coil and S.aureus was investigated by the plate counting method. The results of 12b and 12c showed that the comparative sample 1 and samples 1 to 3 had good antibacterial properties, with the antibacterial rates against E.coil being 97.3%, 99.7%, 99.9% and 99.6%, respectively, and the antibacterial rates against S.aureus being 98.2%, 98.8%, 98.8% and 98.2%, respectively.

[0115] Among them, the comparative sample 1 showed better antibacterial ability mainly because chitosan itself has natural antibacterial properties. The amino groups on its molecular chain combine with free hydrogen to form -NH3 + , and then interact with the negatively charged cell membrane, destroying the integrity of the cell membrane and causing its contents to flow out, thus producing an antibacterial effect. At the same time, the chitosan microparticles prepared by the high-pressure homogenization method are connected to the sponge skeleton in the form of particles through hydroxyl cross-linking and hydrogen bonding, expanding the -NH3 + The exposure probability of the group and the antibacterial performance were improved. Samples 1 to 3 showed better antibacterial performance, which was mainly caused by the catechol group. This polyphenol group can not only react with the enzyme that synthesizes the cell wall to cleave the cell wall, but also change the permeability of the cell membrane, causing the loss of inorganic salt ions and the outflow of cytoplasm.

[0116] Therefore, the modified chitosan microparticle / sodium alginate composite hemostatic sponge exhibits good antibacterial ability and can meet the use requirements of hemostatic materials to deal with bacterial infection of wounds.

[0117] (10) In vitro coagulation index test

[0118] The samples 1 to 3 prepared in Example 1, the comparative sample 1, the commercial hemostatic gauze and the gelatin sponge were tested for in vitro coagulation index, wherein the commercial hemostatic gauze was purchased from Jiangxi Zhizheng Medical Instrument Co., Ltd. and the gelatin sponge was purchased from Jiangxi Xiangen Medical Technology Development Co., Ltd. The test results are as follows: Fig.13 shown.

[0119] The specific method of in vitro coagulation index test is:

[0120] The samples to be tested are samples 1 to 3 prepared in Example 1, comparative sample 1, commercial hemostatic gauze and gelatin sponge. The samples to be tested are fixed to the bottom of the centrifuge tube, and the centrifuge tube and the sheep whole blood test tube are placed in a 37°C water bath for preheating for 5 minutes. Take 5μL of 0.2mol / L CaCl2 solution and disperse it in 50μL of the above preheated whole blood for activation, and then drop the activated blood onto the sample surface. After the centrifuge tube containing the sample is placed at 37°C and incubated for 30s, 60s, 90s, 120s, and 150s, 10mL of deionized water is slowly added to release the uncoagulated blood, and the centrifuge tube is gently shaken to disperse the blood evenly. Finally, the absorbance at 540nm is recorded using an ELISA instrument, and 50μL of anticoagulated blood mixed with 10mL of deionized water is used as a negative control group, and the BCI is calculated by formula (5).

[0121]

[0122] Among them, I s represents the absorbance of the sample, I0 represents the absorbance of deionized water, I r represents the absorbance of the negative control group.

[0123] from Fig.13 It can be seen that the coagulation index of samples 1 to 3 and comparative sample 1 at 150s is lower than that of gelatin sponge and medical gauze, indicating that the composite sponge has a good procoagulant ability. This is closely related to its hydrophilicity. Compared with gelatin sponge, samples 1 to 3 and comparative sample 1 can quickly absorb blood and enter the interior, and the blood is more stable when rinsed with deionized water. However, the gelatin sponge absorbs blood too slowly, and the blood on the surface of the gelatin sponge is dispersed when rinsed with deionized water, and the coagulation index is higher. Compared with hemostatic gauze, although hemostatic gauze can also absorb blood quickly, the structure of samples 1 to 3 and comparative sample 1 is tighter, which can reduce the internal blood dispersion and overflow when rinsed with deionized water and slowly shaken, and thus has a lower coagulation index.

[0124] Among them, samples 1 to 3 have lower coagulation index at 150s than that of control sample 1 because of the introduction of catechol groups to provide adhesion properties for the hemostatic sponge.

[0125] (XI) In vivo coagulation index test

[0126] By establishing a mouse liver injury model and a rat leg artery injury model, the in vivo coagulation index test was performed on the sample 1 and the comparative sample 1 prepared in Example 1. The test results are as follows: Fig.14 shown.

[0127] The specific method of in vivo coagulation index test is:

[0128] Mouse liver injury model: The mice were anesthetized before surgery and fixed on a cork surgical board. The abdominal cavity of the mice was gently cut open with surgical scissors. The tissue fluid around the liver was carefully absorbed with absorbent paper. The liver was punctured at a 30° angle with a 16G needle to induce liver bleeding. Experimental group: The mice immediately used sample 1 and control sample 1 to cover the wound after liver bleeding; gauze group: commercial hemostatic gauze was used to press and stop bleeding; blank group: no treatment was performed. When liver bleeding stopped, the hemostasis time of the mice was recorded in detail, and the amount of bleeding was calculated by the weight difference before and after the hemostatic material.

[0129] Rat femoral artery injury model: The rats were anesthetized before surgery and fixed on a surgical cork board. The thigh epidermis was cut open with surgical scissors, and the deep femoral artery was separated and cut with surgical scissors. Experimental group: Sample 1 and control sample 1 were used for pressing and hemostasis; gauze group: commercial hemostatic gauze was used for pressing and hemostasis; blank group: no treatment was given. After the bleeding of the rat's leg completely stopped, the hemostasis time of the rat was recorded in detail, and the amount of bleeding was calculated by the weight difference before and after the hemostatic material.

[0130] from Fig.14 (a, b, c, d) It can be seen that the bleeding time of the blank, gauze, comparison sample 1 and sample 1 groups were 131s, 68s, 54s and 41s, respectively, and the bleeding volume was 0.194g, 0.063g, 0.059g and 0.065g, respectively. Compared with the blank control group, the hemostasis time of comparison sample 1 and sample 1 was reduced, and the bleeding volume was reduced, but compared with the gauze group, the hemostasis time was not significantly reduced, and the bleeding volume was similar. This reflects that the control effect of comparison sample 1 and sample 1 on the amount of bleeding is not significant, which is due to the high liquid absorption capacity of the hemostatic sponge, which quickly absorbs excess blood.

[0131] from Fig.14 (e, f, g, h) It can be seen that the bleeding time of the blank, gauze, comparative sample 1 and sample 1 groups is 13.32min, 6.91min, 1.77min and 1.59min, respectively, and the bleeding volume is 3.93g, 2.02g, 1.65g and 1.45g, respectively. Therefore, compared with gauze, comparative sample 1 and sample 1 both show faster hemostasis speed and lower bleeding volume in the hemostasis process, showing stronger hemostasis ability. This is because the hemostatic sponge itself can quickly absorb blood and concentrate the coagulation substances on the sponge surface to accelerate coagulation, and the calcium ions in the hemostatic sponge enter the blood as a coagulation factor to accelerate coagulation after the sponge absorbs blood. In addition, compared with comparative sample 1, the coagulation time of sample 1 in the wound is shorter, which is due to the introduction of catechol groups on the surface of the hemostatic sponge after the reaction of protocatechuic aldehyde with chitosan. This active group with the adhesion mechanism of imitating marine mussels provides adhesion properties, which can adhere to blood cells and accelerate coagulation.

[0132] (XII) Crushing and removal test

[0133] The sample 1 and the comparative sample 1 prepared in Example 1 were subjected to a crushing and removal test. The test results are as follows: Fig.15 shown.

[0134] The specific method of the crushing and removal test is:

[0135] The comparison sample 1 and sample 1 sponges swollen with deionized water were subjected to a compression test with a maximum strain of 80%. After compression, the comparison sample 1 was rinsed with 10 ml (0wt%, 0.1wt%, 0.2wt%, 0.3wt% and 0.4wt%) of sodium carbonate solution, and the sample 1 was rinsed with 10 ml (0wt%, 0.2wt%, 0.3wt%, 0.4wt% and 0.5wt%) of sodium carbonate solution. The samples were allowed to stand for 1 min, and the calcium ions and carbonates were initially combined and precipitated to partially release the cross-linking of the calcium ions on the sodium alginate skeleton. Then, the compression test was carried out again.

[0136] The ratio of the compressive strength of the comparison sample 1 and sample 1 after flushing to the compressive strength before flushing is as follows: Fig.15 As shown in a and 15b, as the concentration of sodium carbonate solution increases, the compressive strength of comparison sample 1 and sample 1 shows a downward trend. This is because more calcium ions combine with carbonate to precipitate, the crosslinking degree of calcium ions and sodium alginate decreases, and the compressive strength of the sponge decreases. As the concentration of sodium carbonate solution increases, both comparison sample 1 and sample 1 are partially broken. When the concentration of sodium carbonate solution is 0.4wt%, comparison sample 1 is partially broken after rinsing for 1 minute and cannot maintain the complete morphology. When the concentration of sodium carbonate solution is 0.5wt%, sample 1 is partially broken after rinsing for 1 minute and cannot maintain the complete morphology. This is because the metal coordination between calcium ions and catechol in sample 1 competes with calcium ions, which weakens the binding and precipitation of carbonate ions on calcium ions.

[0137] In order to further characterize the removal effect of sample 1 during the application process, a subsequent hemostatic sponge breakage and dislocation test was performed on the rat femoral artery model in the above (XI) where hemostasis was completed. A 10ml syringe was used to inject 3wt% sodium carbonate solution into the sample, and tweezers were used to assist in cleaning the sponge debris until the hemostatic sponge was completely removed from the wound.

[0138] like Fig.15 As shown in (c, d, f), sample 1 after blood coagulation was gradually broken up by injection and flushing with 3 wt% sodium carbonate. After flushing, the wound surface was clean without any residue, and the integrity of the blood clot in the wound was maintained without causing secondary injury and bleeding.

[0139] The above is a description of a preferred embodiment of the present invention, but it should be understood that the invention is not limited to the contents disclosed herein. As long as non-substantial improvements are made using the method concept and technical solution of the present invention, or the method concept and technical solution of the present invention are applied to other occasions, they are all within the scope of protection of the present invention.

Claims

1. A method for preparing a modified chitosan micron particle / sodium alginate composite hemostatic sponge, It is characterized in that The steps include: (1) dissolving chitosan in an acid solution to prepare a 1-5 wt% chitosan solution, then adding alkali to precipitate the chitosan, filtering and resuspending to obtain a chitosan suspension, and high-pressure homogenizing the chitosan suspension to obtain a chitosan micron particle suspension; (2) mixing a chitosan micron particle suspension with a sodium alginate solution and epichlorohydrin to obtain a mixed solution, and freeze-drying the mixed solution to obtain a chitosan micron particle / sodium alginate composite sponge; (3) Soaking the chitosan micron particle / sodium alginate composite sponge in a calcium chloride solution and a protocatechuic aldehyde solution respectively, and washing, dehydrating and drying the sponge after soaking to obtain a modified chitosan micron particle / sodium alginate composite hemostatic sponge.

2. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 1, It is characterized in that In step (1), deionized water is added to resuspend the chitosan, and the chitosan concentration in the obtained chitosan suspension is ≤2wt%.

3. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 1, It is characterized in that The concentration of sodium alginate in the mixed solution obtained in step (2) is 1 to 5 wt %, and the concentration of epichlorohydrin is 0.1 to 1 wt %.

4. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 1, It is characterized in that The calcium chloride solution in step (3) is a 0.1-2 wt% solution, and the concentration of the protocatechuic aldehyde solution is 0.1-2 wt%.

5. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 2, It is characterized in that In step (1), the acid solution is hydrochloric acid with a concentration of 0.1 mol / L; the alkaline solution is sodium hydroxide solution with a concentration of 1 mol / L. The sodium hydroxide solution is added to make the pH value reach above 9.0 to precipitate chitosan.

6. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 5, It is characterized in that The pressure of the high-pressure homogenization in step (1) is 20 to 50 MPa.

7. The method for preparing the modified chitosan micron particle / sodium alginate composite hemostatic sponge according to claim 4, It is characterized in that In step (3), the components are immersed in a calcium chloride solution and a protocatechuic aldehyde solution respectively, wherein the immersion time in the calcium chloride solution is 0.5 to 4 h, and the immersion time in the protocatechuic aldehyde solution is 0.5 to 4 h.

8. The modified chitosan micron particle / sodium alginate composite hemostatic sponge prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the modified chitosan micron particle / sodium alginate composite hemostatic sponge as claimed in claim 8 in medical hemostasis.

10. The use according to claim 9, It is characterized in that The specific method of medical hemostasis is as follows: when stopping bleeding, the prepared modified chitosan micron particle / sodium alginate composite hemostatic sponge is compressed into a sponge sheet, and the sponge sheet is placed on the wound. The sponge sheet absorbs blood and immediately expands to seal the bleeding wound surface; when removing the wound, a sodium carbonate solution is injected to rinse the sponge until the sponge structure is completely broken and then removed.